Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-09-19

AUTHORS

Koji Nagafuji, Itaru Matsumura, Takayuki Shimose, Tatsuya Kawaguchi, Junya Kuroda, Hirohisa Nakamae, Toshihiro Miyamoto, Norimitsu Kadowaki, Jun Ishikawa, Yutaka Imamura, Hirohito Yamazaki, Koichi Akashi, Yuzuru Kanakura

ABSTRACT

The aim of this multicenter phase 2 trial, Stop Nilotinib (NILSt), was to examine the safety and efficacy of discontinuation of nilotinib in patients with chronic phase (CP)-chronic myelogenous leukemia (CML). Patients with CP-CML who had achieved molecular response (MR4.5) after initiation of imatinib or nilotinib therapy received consolidation therapy with nilotinib 300–400 mg twice daily for up to 24 months. Patients who maintained MR4.5 at 24 months of consolidation therapy proceeded to discontinuation of nilotinib. The study enrolled 149 patients; 112 patients proceeded to consolidation therapy with nilotinib; 90 patients maintained MR4.5 with consolidation therapy, and 87 proceeded to discontinuation of nilotinib. The treatment-free remission (TFR) (MR4.5) rate at both 1 and 3 years after discontinuation of nilotinib was the same, at 60.9% (90% CI 51.6–69.7). Among 34 patients with molecular relapse, nilotinib was resumed in 33 patients; all of them attained MR4.5. There was no significant association between molecular relapse and age, sex, Sokal score, previous interferon-α exposure, duration of tyrosine kinase inhibitors treatment, or trough concentration of nilotinib. With nilotinib, it might be possible to avoid prognostic factors for TFR that exist with imatinib discontinuation. Cessation of nilotinib after two years of consolidation was safe and feasible.Trial registration UMIN000007141. More... »

PAGES

675-682

Journal

TITLE

International Journal of Hematology

ISSUE

6

VOLUME

110

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12185-019-02736-5

DOI

http://dx.doi.org/10.1007/s12185-019-02736-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1121116563

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/31538327


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Consolidation Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Substance Withdrawal Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Withholding Treatment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410781.b", 
          "name": [
            "Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagafuji", 
        "givenName": "Koji", 
        "id": "sg:person.01236323766.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236323766.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Rheumatology, Kindai University, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Hematology and Rheumatology, Kindai University, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsumura", 
        "givenName": "Itaru", 
        "id": "sg:person.0760470165.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Research Support Center Kyushu, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411248.a", 
          "name": [
            "Clinical Research Support Center Kyushu, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimose", 
        "givenName": "Takayuki", 
        "id": "sg:person.010147743535.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010147743535.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawaguchi", 
        "givenName": "Tatsuya", 
        "id": "sg:person.01215475067.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215475067.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272458.e", 
          "name": [
            "Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuroda", 
        "givenName": "Junya", 
        "id": "sg:person.01204610767.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204610767.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Osaka City University, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.261445.0", 
          "name": [
            "Department of Hematology, Osaka City University, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakamae", 
        "givenName": "Hirohisa", 
        "id": "sg:person.01014223462.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.177174.3", 
          "name": [
            "Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyamoto", 
        "givenName": "Toshihiro", 
        "id": "sg:person.01151721224.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151721224.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Kagawa University, Kagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.258331.e", 
          "name": [
            "Department of Internal Medicine, Kagawa University, Kagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kadowaki", 
        "givenName": "Norimitsu", 
        "id": "sg:person.0626745174.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626745174.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416963.f", 
          "name": [
            "Department of Hematology and Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishikawa", 
        "givenName": "Jun", 
        "id": "sg:person.016665023054.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016665023054.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology, St. Mary\u2019s Hospital, Kurume, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416532.7", 
          "name": [
            "Division of Hematology, St. Mary\u2019s Hospital, Kurume, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Imamura", 
        "givenName": "Yutaka", 
        "id": "sg:person.01276172643.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276172643.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412002.5", 
          "name": [
            "Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamazaki", 
        "givenName": "Hirohito", 
        "id": "sg:person.010610305545.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010610305545.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.177174.3", 
          "name": [
            "Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akashi", 
        "givenName": "Koichi", 
        "id": "sg:person.0633204175.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633204175.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Oncology, Osaka University, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136593.b", 
          "name": [
            "Department of Hematology and Oncology, Osaka University, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanakura", 
        "givenName": "Yuzuru", 
        "id": "sg:person.0716216065.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716216065.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12185-017-2295-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090387740", 
          "https://doi.org/10.1007/s12185-017-2295-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2016.104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047140338", 
          "https://doi.org/10.1038/leu.2016.104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2015.29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023059213", 
          "https://doi.org/10.1038/leu.2015.29"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-015-1826-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023749476", 
          "https://doi.org/10.1007/s12185-015-1826-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-09-19", 
    "datePublishedReg": "2019-09-19", 
    "description": "The aim of this multicenter phase 2 trial, Stop Nilotinib (NILSt), was to examine the safety and efficacy of discontinuation of nilotinib in patients with chronic phase (CP)-chronic myelogenous leukemia (CML). Patients with CP-CML who had achieved molecular response (MR4.5) after initiation of imatinib or nilotinib therapy received consolidation therapy with nilotinib 300\u2013400\u00a0mg twice daily for up to 24\u00a0months. Patients who maintained MR4.5 at 24\u00a0months of consolidation therapy proceeded to discontinuation of nilotinib. The study enrolled 149 patients; 112 patients proceeded to consolidation therapy with nilotinib; 90 patients maintained MR4.5 with consolidation therapy, and 87 proceeded to discontinuation of nilotinib. The treatment-free remission (TFR) (MR4.5) rate at both 1 and 3\u00a0years after discontinuation of nilotinib was the same, at 60.9% (90% CI 51.6\u201369.7). Among 34 patients with molecular relapse, nilotinib was resumed in 33 patients; all of them attained MR4.5. There was no significant association between molecular relapse and age, sex, Sokal score, previous interferon-\u03b1 exposure, duration of tyrosine kinase inhibitors treatment, or trough concentration of nilotinib. With nilotinib, it might be possible to avoid prognostic factors for TFR that exist with imatinib discontinuation. Cessation of nilotinib after two years of consolidation was safe and feasible.Trial registration UMIN000007141.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12185-019-02736-5", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.7535205", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "110"
      }
    ], 
    "keywords": [
      "multicenter phase 2 trial", 
      "chronic myelogenous leukemia", 
      "phase 2 trial", 
      "consolidation therapy", 
      "molecular relapse", 
      "myelogenous leukemia", 
      "treatment-free remission (TFR) rates", 
      "tyrosine kinase inhibitor treatment", 
      "initiation of imatinib", 
      "deep molecular response", 
      "kinase inhibitor treatment", 
      "nilotinib 300", 
      "Sokal score", 
      "imatinib discontinuation", 
      "CP-CML", 
      "remission rate", 
      "trough concentrations", 
      "nilotinib therapy", 
      "prognostic factors", 
      "chronic phase", 
      "discontinuation", 
      "molecular response", 
      "patients", 
      "inhibitor treatment", 
      "nilotinib", 
      "therapy", 
      "significant association", 
      "MR4.5", 
      "relapse", 
      "leukemia", 
      "trials", 
      "months", 
      "cessation", 
      "years", 
      "imatinib", 
      "response", 
      "efficacy", 
      "age", 
      "sex", 
      "treatment", 
      "scores", 
      "association", 
      "duration", 
      "safety", 
      "aim", 
      "initiation", 
      "TfR", 
      "factors", 
      "study", 
      "rate", 
      "concentration", 
      "years of consolidation", 
      "consolidation", 
      "phase"
    ], 
    "name": "Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)", 
    "pagination": "675-682", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1121116563"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12185-019-02736-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "31538327"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12185-019-02736-5", 
      "https://app.dimensions.ai/details/publication/pub.1121116563"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_793.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12185-019-02736-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02736-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02736-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02736-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-019-02736-5'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      21 PREDICATES      97 URIs      85 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12185-019-02736-5 schema:about N13935f10e6b24da79acd524bad884179
2 N15afbeca07e44a1b8fce3a3be1ef3187
3 N1745db7e31c34712836e642edca954c3
4 N1b096cf5a68542ea8007e1a4fdddee4e
5 N2531c46393d34879bce345c44ed70555
6 N2a202396d530424d8bf217ce975492ca
7 N6dd1b4ffb9e8492794a4b302df39daca
8 N80fc8c8b6bdd43d3be88301f7f4f9ee5
9 Nb68ff896c5964668ac97c34e8f632371
10 Ndba14fc641ff480c979209c8f261b611
11 Nddf035ed287740129d01178cf2742955
12 Ndf766d828cd64d3c9f7672e3520f041d
13 Nf5f650d8658a49229c6ad62e0fb9ca26
14 Nfb490adf0ed24718886d55f8f30d4fbd
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N158a61d6aac3447e9057e8b753895e52
18 schema:citation sg:pub.10.1007/s12185-015-1826-9
19 sg:pub.10.1007/s12185-017-2295-0
20 sg:pub.10.1038/leu.2015.29
21 sg:pub.10.1038/leu.2016.104
22 schema:datePublished 2019-09-19
23 schema:datePublishedReg 2019-09-19
24 schema:description The aim of this multicenter phase 2 trial, Stop Nilotinib (NILSt), was to examine the safety and efficacy of discontinuation of nilotinib in patients with chronic phase (CP)-chronic myelogenous leukemia (CML). Patients with CP-CML who had achieved molecular response (MR4.5) after initiation of imatinib or nilotinib therapy received consolidation therapy with nilotinib 300–400 mg twice daily for up to 24 months. Patients who maintained MR4.5 at 24 months of consolidation therapy proceeded to discontinuation of nilotinib. The study enrolled 149 patients; 112 patients proceeded to consolidation therapy with nilotinib; 90 patients maintained MR4.5 with consolidation therapy, and 87 proceeded to discontinuation of nilotinib. The treatment-free remission (TFR) (MR4.5) rate at both 1 and 3 years after discontinuation of nilotinib was the same, at 60.9% (90% CI 51.6–69.7). Among 34 patients with molecular relapse, nilotinib was resumed in 33 patients; all of them attained MR4.5. There was no significant association between molecular relapse and age, sex, Sokal score, previous interferon-α exposure, duration of tyrosine kinase inhibitors treatment, or trough concentration of nilotinib. With nilotinib, it might be possible to avoid prognostic factors for TFR that exist with imatinib discontinuation. Cessation of nilotinib after two years of consolidation was safe and feasible.Trial registration UMIN000007141.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N0de6ea550cd0452d883d39ab17f7c867
28 N38f2601110cb43a7b9c510245e7f9f26
29 sg:journal.1076985
30 schema:keywords CP-CML
31 MR4.5
32 Sokal score
33 TfR
34 age
35 aim
36 association
37 cessation
38 chronic myelogenous leukemia
39 chronic phase
40 concentration
41 consolidation
42 consolidation therapy
43 deep molecular response
44 discontinuation
45 duration
46 efficacy
47 factors
48 imatinib
49 imatinib discontinuation
50 inhibitor treatment
51 initiation
52 initiation of imatinib
53 kinase inhibitor treatment
54 leukemia
55 molecular relapse
56 molecular response
57 months
58 multicenter phase 2 trial
59 myelogenous leukemia
60 nilotinib
61 nilotinib 300
62 nilotinib therapy
63 patients
64 phase
65 phase 2 trial
66 prognostic factors
67 rate
68 relapse
69 remission rate
70 response
71 safety
72 scores
73 sex
74 significant association
75 study
76 therapy
77 treatment
78 treatment-free remission (TFR) rates
79 trials
80 trough concentrations
81 tyrosine kinase inhibitor treatment
82 years
83 years of consolidation
84 schema:name Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)
85 schema:pagination 675-682
86 schema:productId N256b06828efd4494abfc9c0c1fbb018e
87 N2af04590d73a495f886df2a1fcb12b0a
88 N79e58f6e37e34a07aa23f5af8c3590a6
89 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121116563
90 https://doi.org/10.1007/s12185-019-02736-5
91 schema:sdDatePublished 2022-12-01T06:38
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N1c2778cf84b644a0a1e794f3dd12747a
94 schema:url https://doi.org/10.1007/s12185-019-02736-5
95 sgo:license sg:explorer/license/
96 sgo:sdDataset articles
97 rdf:type schema:ScholarlyArticle
98 N0de6ea550cd0452d883d39ab17f7c867 schema:issueNumber 6
99 rdf:type schema:PublicationIssue
100 N13935f10e6b24da79acd524bad884179 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Adult
102 rdf:type schema:DefinedTerm
103 N158a61d6aac3447e9057e8b753895e52 rdf:first sg:person.01236323766.31
104 rdf:rest N75c140c5ad344c39ac79bd2f89120df5
105 N15afbeca07e44a1b8fce3a3be1ef3187 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Female
107 rdf:type schema:DefinedTerm
108 N1745db7e31c34712836e642edca954c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N1b096cf5a68542ea8007e1a4fdddee4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Recurrence
113 rdf:type schema:DefinedTerm
114 N1c2778cf84b644a0a1e794f3dd12747a schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 N1f8b1796af7b43a0a7f383cf689138af rdf:first sg:person.0716216065.38
117 rdf:rest rdf:nil
118 N2531c46393d34879bce345c44ed70555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Leukemia, Myelogenous, Chronic, BCR-ABL Positive
120 rdf:type schema:DefinedTerm
121 N256b06828efd4494abfc9c0c1fbb018e schema:name doi
122 schema:value 10.1007/s12185-019-02736-5
123 rdf:type schema:PropertyValue
124 N2a202396d530424d8bf217ce975492ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Withholding Treatment
126 rdf:type schema:DefinedTerm
127 N2af04590d73a495f886df2a1fcb12b0a schema:name pubmed_id
128 schema:value 31538327
129 rdf:type schema:PropertyValue
130 N38f2601110cb43a7b9c510245e7f9f26 schema:volumeNumber 110
131 rdf:type schema:PublicationVolume
132 N3e6cf06268914f308ccd33ea9dfa0d5c rdf:first sg:person.01276172643.71
133 rdf:rest N680574a16f0341b5bd55255643baad38
134 N5c3826ac943b40a9b23f018fd150aca8 rdf:first sg:person.010147743535.36
135 rdf:rest Nf92ce4cda2664d01acf7f5ccecdc4e63
136 N680574a16f0341b5bd55255643baad38 rdf:first sg:person.010610305545.12
137 rdf:rest Nccb51374f4df442eac871e6d68729241
138 N6dd1b4ffb9e8492794a4b302df39daca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Substance Withdrawal Syndrome
140 rdf:type schema:DefinedTerm
141 N75c140c5ad344c39ac79bd2f89120df5 rdf:first sg:person.0760470165.13
142 rdf:rest N5c3826ac943b40a9b23f018fd150aca8
143 N79e58f6e37e34a07aa23f5af8c3590a6 schema:name dimensions_id
144 schema:value pub.1121116563
145 rdf:type schema:PropertyValue
146 N80fc8c8b6bdd43d3be88301f7f4f9ee5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Middle Aged
148 rdf:type schema:DefinedTerm
149 Nb68ff896c5964668ac97c34e8f632371 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Remission Induction
151 rdf:type schema:DefinedTerm
152 Nc058154737474f40b59bae3af0d2649a rdf:first sg:person.01014223462.98
153 rdf:rest Ne88829735326431fadc5e704baafe1fc
154 Ncc4f1a2f8c1f45f985ea75ec7c7f41d7 rdf:first sg:person.01204610767.63
155 rdf:rest Nc058154737474f40b59bae3af0d2649a
156 Nccb51374f4df442eac871e6d68729241 rdf:first sg:person.0633204175.29
157 rdf:rest N1f8b1796af7b43a0a7f383cf689138af
158 Ndae96d40847d4446a51764cd3a70ac44 rdf:first sg:person.0626745174.45
159 rdf:rest Nf16870aa45d141fb9ff494ee0f8c4d13
160 Ndba14fc641ff480c979209c8f261b611 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Consolidation Chemotherapy
162 rdf:type schema:DefinedTerm
163 Nddf035ed287740129d01178cf2742955 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aged
165 rdf:type schema:DefinedTerm
166 Ndf766d828cd64d3c9f7672e3520f041d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Pyrimidines
168 rdf:type schema:DefinedTerm
169 Ne88829735326431fadc5e704baafe1fc rdf:first sg:person.01151721224.39
170 rdf:rest Ndae96d40847d4446a51764cd3a70ac44
171 Nf16870aa45d141fb9ff494ee0f8c4d13 rdf:first sg:person.016665023054.88
172 rdf:rest N3e6cf06268914f308ccd33ea9dfa0d5c
173 Nf5f650d8658a49229c6ad62e0fb9ca26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Male
175 rdf:type schema:DefinedTerm
176 Nf92ce4cda2664d01acf7f5ccecdc4e63 rdf:first sg:person.01215475067.73
177 rdf:rest Ncc4f1a2f8c1f45f985ea75ec7c7f41d7
178 Nfb490adf0ed24718886d55f8f30d4fbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Imatinib Mesylate
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
185 schema:name Clinical Sciences
186 rdf:type schema:DefinedTerm
187 sg:grant.7535205 http://pending.schema.org/fundedItem sg:pub.10.1007/s12185-019-02736-5
188 rdf:type schema:MonetaryGrant
189 sg:journal.1076985 schema:issn 0925-5710
190 1865-3774
191 schema:name International Journal of Hematology
192 schema:publisher Springer Nature
193 rdf:type schema:Periodical
194 sg:person.01014223462.98 schema:affiliation grid-institutes:grid.261445.0
195 schema:familyName Nakamae
196 schema:givenName Hirohisa
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014223462.98
198 rdf:type schema:Person
199 sg:person.010147743535.36 schema:affiliation grid-institutes:grid.411248.a
200 schema:familyName Shimose
201 schema:givenName Takayuki
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010147743535.36
203 rdf:type schema:Person
204 sg:person.010610305545.12 schema:affiliation grid-institutes:grid.412002.5
205 schema:familyName Yamazaki
206 schema:givenName Hirohito
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010610305545.12
208 rdf:type schema:Person
209 sg:person.01151721224.39 schema:affiliation grid-institutes:grid.177174.3
210 schema:familyName Miyamoto
211 schema:givenName Toshihiro
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151721224.39
213 rdf:type schema:Person
214 sg:person.01204610767.63 schema:affiliation grid-institutes:grid.272458.e
215 schema:familyName Kuroda
216 schema:givenName Junya
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204610767.63
218 rdf:type schema:Person
219 sg:person.01215475067.73 schema:affiliation grid-institutes:grid.274841.c
220 schema:familyName Kawaguchi
221 schema:givenName Tatsuya
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215475067.73
223 rdf:type schema:Person
224 sg:person.01236323766.31 schema:affiliation grid-institutes:grid.410781.b
225 schema:familyName Nagafuji
226 schema:givenName Koji
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236323766.31
228 rdf:type schema:Person
229 sg:person.01276172643.71 schema:affiliation grid-institutes:grid.416532.7
230 schema:familyName Imamura
231 schema:givenName Yutaka
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276172643.71
233 rdf:type schema:Person
234 sg:person.016665023054.88 schema:affiliation grid-institutes:grid.416963.f
235 schema:familyName Ishikawa
236 schema:givenName Jun
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016665023054.88
238 rdf:type schema:Person
239 sg:person.0626745174.45 schema:affiliation grid-institutes:grid.258331.e
240 schema:familyName Kadowaki
241 schema:givenName Norimitsu
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626745174.45
243 rdf:type schema:Person
244 sg:person.0633204175.29 schema:affiliation grid-institutes:grid.177174.3
245 schema:familyName Akashi
246 schema:givenName Koichi
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0633204175.29
248 rdf:type schema:Person
249 sg:person.0716216065.38 schema:affiliation grid-institutes:grid.136593.b
250 schema:familyName Kanakura
251 schema:givenName Yuzuru
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716216065.38
253 rdf:type schema:Person
254 sg:person.0760470165.13 schema:affiliation grid-institutes:grid.258622.9
255 schema:familyName Matsumura
256 schema:givenName Itaru
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760470165.13
258 rdf:type schema:Person
259 sg:pub.10.1007/s12185-015-1826-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023749476
260 https://doi.org/10.1007/s12185-015-1826-9
261 rdf:type schema:CreativeWork
262 sg:pub.10.1007/s12185-017-2295-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090387740
263 https://doi.org/10.1007/s12185-017-2295-0
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/leu.2015.29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023059213
266 https://doi.org/10.1038/leu.2015.29
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/leu.2016.104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047140338
269 https://doi.org/10.1038/leu.2016.104
270 rdf:type schema:CreativeWork
271 grid-institutes:grid.136593.b schema:alternateName Department of Hematology and Oncology, Osaka University, Osaka, Japan
272 schema:name Department of Hematology and Oncology, Osaka University, Osaka, Japan
273 rdf:type schema:Organization
274 grid-institutes:grid.177174.3 schema:alternateName Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan
275 schema:name Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan
276 rdf:type schema:Organization
277 grid-institutes:grid.258331.e schema:alternateName Department of Internal Medicine, Kagawa University, Kagawa, Japan
278 schema:name Department of Internal Medicine, Kagawa University, Kagawa, Japan
279 rdf:type schema:Organization
280 grid-institutes:grid.258622.9 schema:alternateName Department of Hematology and Rheumatology, Kindai University, Osaka, Japan
281 schema:name Department of Hematology and Rheumatology, Kindai University, Osaka, Japan
282 rdf:type schema:Organization
283 grid-institutes:grid.261445.0 schema:alternateName Department of Hematology, Osaka City University, Osaka, Japan
284 schema:name Department of Hematology, Osaka City University, Osaka, Japan
285 rdf:type schema:Organization
286 grid-institutes:grid.272458.e schema:alternateName Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
287 schema:name Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
288 rdf:type schema:Organization
289 grid-institutes:grid.274841.c schema:alternateName Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan
290 schema:name Department of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan
291 rdf:type schema:Organization
292 grid-institutes:grid.410781.b schema:alternateName Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Japan
293 schema:name Division of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Japan
294 rdf:type schema:Organization
295 grid-institutes:grid.411248.a schema:alternateName Clinical Research Support Center Kyushu, Fukuoka, Japan
296 schema:name Clinical Research Support Center Kyushu, Fukuoka, Japan
297 rdf:type schema:Organization
298 grid-institutes:grid.412002.5 schema:alternateName Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan
299 schema:name Division of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan
300 rdf:type schema:Organization
301 grid-institutes:grid.416532.7 schema:alternateName Division of Hematology, St. Mary’s Hospital, Kurume, Japan
302 schema:name Division of Hematology, St. Mary’s Hospital, Kurume, Japan
303 rdf:type schema:Organization
304 grid-institutes:grid.416963.f schema:alternateName Department of Hematology and Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
305 schema:name Department of Hematology and Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...